Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
rivasterat (CU06) / Thea Laboratories
NCT05573100: The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)	Completed	2	67	US	CU06-1004, SAC-1004, CU06, CU06-RE	Curacle Co., Ltd., Théa Open Innovation, France	Diabetic Macular Edema	05/23	06/23
UC, NCT05907330: Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis	Not yet recruiting	2	45	NA	CU104, Placebo	Curacle Co., Ltd.	Ulcerative Colitis	02/26	03/26
dimethyl fumarate (CU01) / Curacle
NCT05718375: Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria	Recruiting	2b	240	RoW	CU01-1001, Placebo	Curacle Co., Ltd.	Diabetic Nephropathies	09/24	09/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
rivasterat (CU06) / Thea Laboratories
NCT05573100: The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)	Completed	2	67	US	CU06-1004, SAC-1004, CU06, CU06-RE	Curacle Co., Ltd., Théa Open Innovation, France	Diabetic Macular Edema	05/23	06/23
UC, NCT05907330: Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis	Not yet recruiting	2	45	NA	CU104, Placebo	Curacle Co., Ltd.	Ulcerative Colitis	02/26	03/26
dimethyl fumarate (CU01) / Curacle
NCT05718375: Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria	Recruiting	2b	240	RoW	CU01-1001, Placebo	Curacle Co., Ltd.	Diabetic Nephropathies	09/24	09/24